Online Exclusive Article

Hyperglycemic-Inducing Neoadjuvant Agents Used in Treatment of Solid Tumors: A Review of the Literature

Denise S. Hershey

Ashley Leak Bryant

Jill Olausson

Ellen Davis

Veronica J. Brady

Marilyn J. Hammer
neoplasm, chemotherapy, hyperglycemia
ONF 2014, 41(6), E343-E354. DOI: 10.1188/14.ONF.E343-E354

Purpose/Objectives: To review the literature regarding the development of hyperglycemia associated with neoadjuvant agents used in the treatment of solid tumor cancers.

Data Sources: Research articles were obtained from PubMed, CINAHL®, and Cochrane Reviews. The following search terms were used alone and in combination: diabetes, glycemic control, chemotherapy, androgen deprivation therapy, interferon-alpha, immunosuppressants, cancer, neoplasms, and hyperglycemia.

Data Synthesis: Twenty-two studies were identified reporting the development of hyperglycemic events in patients who received a variety of chemotherapeutic agents.

Conclusions: Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes.

Implications for Nursing: Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes in patients with a solid tumor cancer who are at risk for treatment-induced hyperglycemia.

Jump to a section


    Ali, N. A., O'Brien, J. M., Jr., Blum, W., Byrd, J. C., Klisovic, R. B., Marcucci, G., … Grever, M. R. (2007). Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer, 110, 96-102.
    Barone, B., Yeh, H., Snyder, C., Peairs, K., Stein, K., Derr, R., … Brancati, F. (2008). Long-term all-cause mortality in cancer patients with preexisting diabetis mellitus: A systematic review and meta-analysis. JAMA, 300, 2754-2764. doi:10.1001/jama.2008.824
    Basaria, S. (2008). Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. Journal of Andrology, 29, 534-539.
    Basaria, S., Muller, D. C., Carducci, M. A., Egan, J., & Dobs, A. S. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106, 581-588.
    Baselga, J., Campone, M., Piccart, M., Burris, H. A., III, Rugo, H. S., Sahmoud, T., … Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine, 366, 520-529.
    Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., … Clow, F. W. (2007). Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. Journal of Clinical Oncology, 25, 669-674.
    Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., & Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 19, 1387-1392.
    Bex, A., Mallo, H., Kerst, M., Haanen, J., Horenblas, S., & de Gast, G. C. (2005). A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunology, Immunotherapy, 54, 713-719.
    Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology, 24, 3979-3983.
    Brunello, A., Kapoor, R., & Extermann, M. (2011). Hyperglycemic during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. American Journal of Clinical Oncology, 34, 292-296. doi:10.1097/coc.0b013e3181e1d0c0
    Derweesh, I. H., Diblasio, C. J., Kincade, M. C., Malcolm, J. B., Lamar, K. D., Patterson, A. L., … Wake, R. W. (2007). Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International, 100, 1060-1065.
    Feliu, J., Martin, G., Lizon, J., Chacon, J. I., Dorta, J., de Castro, J., … Gonzalez Baron, M. (2001). Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. Annals of Oncology, 12, 1369-1374.
    Feng, J. P., Yuan, X. L., Li, M., Fang, J., Xie, T., Zhou, Y., … Ye, D. W. (2012). Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: Results from a single centre cohort study. Colorectal Disease, 17, 1463-1318.
    Fuji, S., Kim, S., Mori, S., Fukuda, T., Kamiya, S., Yamasaki, S., … Takaue, Y. (2007). Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation, 84, 814-820.
    Fury, M. G., Sherman, E., Haque, S., Korte, S., Lisa, D., Shen, R., … Pfister, D. (2012). A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 69, 591-598.
    Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., … Walsh, D. J. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. Journal of Clinical Oncology, 23, 5294-5304.
    Giovanucci, E., Harlan, D., Archer, M., Bergenstal, R., Gapstur, S., Habel, L., … Yee, D. (2010). Diabetes and cancer: A consensus report. CA: A Cancer Journal for Clinicians, 60, 207-221.
    Godbout, J. P., & Glaser, R. (2006). Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. Journal of Neuroimmune Pharmacology, 1, 421-427.
    Grivennikov, S. I., & Karin, M. (2011). Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Annals of the Rheumatic Diseases, 70(Suppl. 1), i104-i108.
    Hakimian, P., Blute, M., Jr., Kashanian, J., Chan, S., Silver, D., & Shabsigh, R. (2008). Metabolic and cardiovascular effects of androgen deprivation therapy. BJU International, 102, 1509-1514.
    Hammer, M. J., Casper, C., Gooley, T. A., O'Donnell, P. V., Boeckh, M., & Hirsch, I. B. (2009). The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biology of Blood and Marrow Transplantation, 15, 344-351.
    Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., … Motzer, R. J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356, 2271-2281.
    Inaba, M., Otani, Y., Nishimura, K., Takaha, N., Okuyama, A., Koga, M., … Kasayama, S. (2005). Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism, 54, 55-59.
    Infante, J. R., Yardley, D. A., Burris, H. A., III, Greco, F. A., Farley, C. P., Webb, C., … Hainsworth, J. D. (2009). Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clinical Breast Cancer, 9, 23-28.
    Jenkins, D. J., Kendall, C. W., Augustin, L. S., Franceschi, S., Hamidi, M., Marchie, A., … Axelsen, M. (2002). Glycemic index: Overview of implications in health and disease. American Journal of Clinical Nutrition, 76, 266S-273S.
    Katz, A. (2007). Modulation of glucose transport in skeletal muscle by reactive oxygen species. Journal of Applied Physiology, 102, 1671-1676.
    Leak, A., Davis, E., Houchin, L., & Mabrey, M. (2009). Diabetes management and self-care education for hospitalized patients with cancer. Clinical Journal of Oncology Nursing, 13, 205-210.
    Lee, Y. J., Doliny, P., Gomez-Fernandez, C., Powell, J., Reis, I., & Hurley, J. (2004). Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clinical Breast Cancer, 5, 371-376.
    Lim, T., Lee, J., Lee, D., Lee, H., Han, B., Baek, K., … Kim, W. (2011). Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 68, 255-262.
    Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436-444.
    Martin-Salces, M., de Paz, R., Canales, M. A., Mesejo, A., & Hernandez-Navarro, F. (2008). Nutritional recommendations in hematopoietic stem cell transplantation. Nutrition, 24, 769-775.
    Meyerhardt, J., Catalano, P., Haller, D., Mayer, R., Macdonald, J., Benson A., III, & Fuchs, C. (2003). Impact of diabetes on outcomes in patients with colon cancer. Journal of Clinical Oncology, 21, 443-440.
    Moien-Afshari, F., Ghosh, S., Khazaei, M., Kieffer, T. J., Brownsey, R. W., & Laher, I. (2008). Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. Diabetologia, 51, 1327-1337. doi:10.1007/s00125-008-0996-x
    Moretti, M., Bennett, J., Tornatore, L., Thotakura, A. K., & Franzoso, G. (2012). Cancer: NF-kappaB regulates energy metabolism. International Journal of Biochemistry and Cell Biology, 10, 10.
    Naing, A., Kurzrock, R., Burger, A., Gupta, S., Lei, X., Busaidy, N., … LoRusso, P. (2011). Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clinical Cancer Research, 17, 6052-6060.
    National Institutes of Health. (2010). National diabetes statistics, 2011. Retrieved from
    Okabe, S., Ishikawa, T., Tanami, H., Kuwabara, H., Fukahara, T., Udagawa, M., … Iwai, T. (2002). Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. Journal of Medical and Dental Sciences, 49, 77-84.
    Psarakis, H. (2006). Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum, 19, 157-162.
    Ribeiro, A. F., Camara, C., Segre, C. A., Srougi, M., & Serrano, C. V., Jr. (2010). Cardiovascular risks of androgen deprivation therapy. Arquivos Brasileiros De Cardiologia, 95, 412-415.
    Richardson, L., & Pollack, L. (2005). Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice Oncology, 2, 48-53. doi:10.1038/ncponc0062
    Roumen, C., Blaak, E. E., & Corpeleijn, E. (2009). Lifestyle intervention for prevention of diabetes: determinants of success for future implementation. Nutrition Reviews, 67, 132-146.
    Spigel, D. R., Greco, F. A., Meluch, A. A., Lane, C. M., Farley, C., Gray, J. R., … Hainsworth, J. D. (2010). Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Journal of Clinical Oncology, 28, 2213-2219. doi:10.1200/jco.2009.24.8773
    Stookey, J. D., Pieper, C. F., & Cohen, H. J. (2004). Hypertonic hyperglycemia progresses to diabetes faster than normotonic hyperglycemia. European Journal of Epidemiology, 19, 935-944.
    Storey, S., & Von Ah, D. (2012). Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: A review of the literature. Oncology Nursing Forum, 39, 458-465. doi:10.1188/12.ONF.458-465
    Turina, M., Christ-Crain, M., & Polk, H., Jr. (2006). Diabetes and hyperglycemia: Strict glycemic control. Critical Care Medicine, 34 (9, Suppl.), S291-S300.
    U. S. Department of Health and Human Services. (2013). Aging statistics. Retrieved from
    Zeng, L., Biernacka, K., Holly, J., Jarrett, C., Morrison, A., Morgan, A., … Perks, C. (2010). Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-Related Cancer, 17, 539-551. doi:10.0677/ERC-09-0221